Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycolic Acid SCHEMBL5031495 | 0.86 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| Propionic Acid SCHEMBL5026941 | 0.86 | FFAR3 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| Acetic Acid SCHEMBL5027741 | 0.85 | PIK3CD (0.48) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL174185 | 0.84 | — | — | |
| Iodide SCHEMBL5017287 | 0.81 | — | — | |
| SCHEMBL11230541 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL10570933 | 0.81 | — | — | |
| SCHEMBL27389859 | 0.79 | CHRNB2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL27753057 | 0.78 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| Acetic Acid SCHEMBL27845271 | 0.78 | CHRM1 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160017540-A1 | PRETREATMENT AND FRACTIONATION OF LIGNOCELLULOSIC BIOMASS | SUGANIT SYSTEMS, INC. | 2016-01-21 | — | — | US | claimed |
| EP-2971190-A1 | ALKALINE TREATMENT OF LIGNOCELLULOSIC BIOMASS | Suganit Systems, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014144588-A1 | ALKALINE TREATMENT OF LIGNOCELLULOSIC BIOMASS | SUGANIT SYSTEMS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| WO-2025034877-A2 | SOLUTION SPINNING OF PROTEIN-CELLULOSIC BLEND FIBERS | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20160017540-A1 | PRETREATMENT AND FRACTIONATION OF LIGNOCELLULOSIC BIOMASS | SUGANIT SYSTEMS, INC. | 2016-01-21 | — | — | US | disclosed |
| EP-2971190-A1 | ALKALINE TREATMENT OF LIGNOCELLULOSIC BIOMASS | Suganit Systems, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150259571-A1 | LIGNIN MEMBRANES AND COATINGS | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2015-09-17 | — | — | US | disclosed |
| WO-2014144588-A1 | ALKALINE TREATMENT OF LIGNOCELLULOSIC BIOMASS | SUGANIT SYSTEMS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014035498-A1 | LIGNIN MEMBRANES AND COATINGS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2010136105-A2 | AMMONIUMCARBOXYLATES | MERCK PATENT GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
| CN-101316810-A | Ionic liquids | BIONIQS LTD (GB) | 2008-12-03 | — | — | CN | disclosed |
| US-20080221361-A1 | Ionic Liquids | BIONIQS LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160017540-A1 | PRETREATMENT AND FRACTIONATION OF LIGNOCELLULOSIC BIOMASS | LCT, MGAM, ENGASE | CHRM2 2693/4885CHRM4 2651/4885CHRM5 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.